Ubs Group Ag Amarin Corp Plcuk Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Amarin Corp Plcuk stock. As of the latest transaction made, Ubs Group Ag holds 658,326 shares of AMRN stock, worth $362,079. This represents 0.0% of its overall portfolio holdings.

Number of Shares

658,326

Previous 462,092 42.47%

Holding current value

$362,079

Previous $318,000 30.19%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.57 - $0.8 $111,853 - $156,987	196,234 Added 42.47%	658,326 $414,000
Q2 2024 Aug 13, 2024	BUY	$0.63 - $1.07 $12,586 - $21,377	19,979 Added 4.52%	462,092 $318,000
Q1 2024 May 13, 2024	SELL	$0.82 - $1.35 $197,172 - $324,612	-240,454 Reduced 35.23%	442,113 $393,000
Q4 2023 Feb 09, 2024	SELL	$0.66 - $0.91 $47,557 - $65,571	-72,057 Reduced 9.55%	682,567 $593,000
Q3 2023 Nov 09, 2023	BUY	$0.85 - $1.43 $12,251 - $20,610	14,413 Added 1.95%	754,624 $694,000
Q2 2023 Aug 11, 2023	BUY	$1.12 - $1.49 $724 - $964	647 Added 0.09%	740,211 $880,000
Q1 2023 May 12, 2023	SELL	$1.19 - $2.19 $38,744 - $71,302	-32,558 Reduced 4.22%	739,564 $1.11 Million
Q4 2022 Feb 08, 2023	SELL	$1.07 - $1.34 $105,935 - $132,666	-99,005 Reduced 11.37%	772,122 $934,000
Q3 2022 Nov 10, 2022	SELL	$1.09 - $1.67 $17,393 - $26,648	-15,957 Reduced 1.8%	871,127 $950,000
Q2 2022 Aug 10, 2022	BUY	$1.13 - $3.69 $7,913 - $25,841	7,003 Added 0.8%	887,084 $1.32 Million
Q1 2022 May 16, 2022	BUY	$2.85 - $3.73 $8,532 - $11,167	2,994 Added 0.34%	880,081 $2.9 Million
Q4 2021 Feb 14, 2022	BUY	$3.24 - $5.18 $177,004 - $282,988	54,631 Added 6.64%	877,087 $2.96 Million
Q3 2021 Nov 15, 2021	SELL	$3.94 - $5.84 $5,610 - $8,316	-1,424 Reduced 0.17%	822,456 $4.2 Million
Q2 2021 Aug 13, 2021	BUY	$4.26 - $6.5 $72,867 - $111,182	17,105 Added 2.12%	823,880 $3.61 Million
Q1 2021 May 12, 2021	BUY	$5.03 - $8.8 $1.03 Million - $1.79 Million	203,872 Added 33.82%	806,775 $5.01 Million
Q4 2020 Feb 11, 2021	SELL	$4.04 - $5.31 $73,184 - $96,190	-18,115 Reduced 2.92%	602,903 $2.95 Million
Q3 2020 Nov 12, 2020	SELL	$3.64 - $7.76 $199,850 - $426,055	-54,904 Reduced 8.12%	621,018 $2.62 Million
Q2 2020 Jul 31, 2020	BUY	$4.78 - $8.26 $103,802 - $179,374	21,716 Added 3.32%	675,922 $4.68 Million
Q1 2020 May 01, 2020	SELL	$4.0 - $21.53 $231,064 - $1.24 Million	-57,766 Reduced 8.11%	654,206 $2.62 Million
Q4 2019 Feb 14, 2020	BUY	$13.94 - $24.12 $555,188 - $960,627	39,827 Added 5.93%	711,972 $15.3 Million
Q3 2019 Nov 14, 2019	BUY	$13.89 - $23.16 $1.41 Million - $2.35 Million	101,633 Added 17.81%	672,145 $10.2 Million
Q2 2019 Aug 14, 2019	SELL	$16.27 - $20.51 $2.95 Million - $3.72 Million	-181,277 Reduced 24.11%	570,512 $11.1 Million
Q1 2019 May 14, 2019	SELL	$12.61 - $22.33 $3.38 Million - $5.99 Million	-268,327 Reduced 26.3%	751,789 $15.6 Million
Q4 2018 Feb 14, 2019	BUY	$12.41 - $22.98 $1.03 Million - $1.91 Million	83,327 Added 8.89%	1,020,116 $13.9 Million
Q3 2018 Nov 14, 2018	BUY	$2.45 - $16.27 $409,787 - $2.72 Million	167,260 Added 21.74%	936,789 $15.2 Million
Q2 2018 Aug 14, 2018	BUY	$2.68 - $3.48 $20,523 - $26,649	7,658 Added 1.01%	769,529 $2.38 Million
Q1 2018 May 15, 2018	SELL	$2.99 - $4.44 $13,305 - $19,758	-4,450 Reduced 0.58%	761,871 $2.29 Million
Q4 2017 Feb 14, 2018	BUY	$3.06 - $4.09 $82,344 - $110,061	26,910 Added 3.64%	766,321 $3.07 Million
Q3 2017 Nov 14, 2017	SELL	$3.03 - $3.72 $78,989 - $96,976	-26,069 Reduced 3.41%	739,411 $2.59 Million
Q2 2017 Aug 14, 2017	BUY	N/A	33,962 Added 4.64%	765,480 $3.09 Million
Q1 2017 Nov 14, 2017	BUY	N/A	731,518	731,518 $2.34 Million

Others Institutions Holding AMRN

# of Institutions

177

Shares Held

65.1M

Call Options Held

258K

Put Options Held

98K

View Full List

About AMARIN CORP PLCUK

Ticker AMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 403,206,016
Market Cap $222M
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...

More about AMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account